## Filomena Morisco

## List of Publications by Year in Descending Order

Source: https://exaly.com/author-pdf/6730820/filomena-morisco-publications-by-year.pdf

Version: 2024-04-28

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

3,862 149 31 57 h-index g-index citations papers 160 4.69 4,918 5.3 L-index avg, IF ext. citations ext. papers

#	Paper	IF	Citations
149	Beneficial Effects of Silybin Treatment After Viral Eradication in Patients With HCV-Related Advanced Chronic Liver Disease: A Pilot Study <i>Frontiers in Pharmacology</i> , <b>2022</b> , 13, 824879	5.6	
148	COVID-19 in liver transplant recipients: incidence, hospitalization and outcome in an Italian prospective double-centre study <i>Scientific Reports</i> , <b>2022</b> , 12, 4831	4.9	1
147	Gender and Autoimmune Liver Diseases: Relevant Aspects in Clinical Practice. <i>Journal of Personalized Medicine</i> , <b>2022</b> , 12, 925	3.6	О
146	Hepatitis B vaccine coverage and risk factors for lack of vaccination in subjects with HBsAg negative liver cirrhosis in Italy: still, much work should be done. <i>Digestive and Liver Disease</i> , <b>2021</b> , 53, 1315-1319	3.3	2
145	A prospective study of DAA Effectiveness and Relapse Risk in HCV Cryoglobulinemic Vasculitis by the Italian PITER Cohort <i>Hepatology</i> , <b>2021</b> ,	11.2	3
144	PNPLA3, TM6SF2, and MBOAT7 Influence on Nutraceutical Therapy Response for Non-alcoholic Fatty Liver Disease: A Randomized Controlled Trial. <i>Frontiers in Medicine</i> , <b>2021</b> , 8, 734847	4.9	4
143	Material deprivation affects the management and clinical outcome of hepatocellular carcinoma in a high-resource environment. <i>European Journal of Cancer</i> , <b>2021</b> , 158, 133-143	7.5	
142	Pattern of macrovascular invasion in hepatocellular carcinoma. <i>European Journal of Clinical Investigation</i> , <b>2021</b> , 51, e13542	4.6	5
141	The Combination of Berberine, Tocotrienols and Coffee Extracts Improves Metabolic Profile and Liver Steatosis by the Modulation of Gut Microbiota and Hepatic miR-122 and miR-34a Expression in Mice. <i>Nutrients</i> , <b>2021</b> , 13,	6.7	3
140	Clinical features and comorbidity pattern of HCV infected migrants compared to native patients in care in Italy: A real-life evaluation of the PITER cohort. <i>Digestive and Liver Disease</i> , <b>2021</b> , 53, 1603-1609	3.3	
139	A Nomogram-Based Prognostic Model for Advanced Hepatocellular Carcinoma Patients Treated with Sorafenib: A Multicenter Study. <i>Cancers</i> , <b>2021</b> , 13,	6.6	1
138	Recalibrating survival prediction among patients receiving trans-arterial chemoembolization for hepatocellular carcinoma. <i>Liver Cancer International</i> , <b>2021</b> , 2, 45-53	0.8	1
137	Performance of the model for end-stage liver disease score for mortality prediction and the potential role of etiology. <i>Journal of Hepatology</i> , <b>2021</b> , 75, 1355-1366	13.4	2
136	Risk Factors for Liver Decompensation and HCC in HCV-Cirrhotic Patients after DAAs: A Multicenter Prospective Study. <i>Cancers</i> , <b>2021</b> , 13,	6.6	4
135	Monofocal hepatocellular carcinoma: How much does size matter?. Liver International, 2021, 41, 396-40	<b>7</b> 7.9	7
134	Effectiveness and safety of glecaprevir/pibrentasvir in chronic hepatitis C patients: Results of the Italian cohort of a post-marketing observational study. <i>Digestive and Liver Disease</i> , <b>2021</b> , 53, 612-619	3.3	3
133	Chronic hepatitis B virus infection in Italy during the twenty-first century: an updated survey in 2019. European Journal of Clinical Microbiology and Infectious Diseases, <b>2021</b> , 40, 607-614	5.3	3

The changing scenario of hepatocellular carcinoma in Italy: an update. Liver International, 2021, 41, 585-593 132 25 Metabolic-associated fatty liver disease (MAFLD) in coeliac disease. Liver International, 2021, 41, 788-798, 9 131 On-treatment serum albumin level can guide long-term treatment in patients with cirrhosis and 130 13.4 11 uncomplicated ascites. Journal of Hepatology, 2021, 74, 340-349 Changes in hepatocellular carcinoma aggressiveness characteristics with an increase in tumor 2.8 129 diameter. International Journal of Biological Markers, 2021, 36, 54-61 Comparison of prognostic models in advanced hepatocellular carcinoma patients undergoing 128 6 3.3 Sorafenib: A multicenter study. Digestive and Liver Disease, 2021, 53, 1011-1019 Effectiveness of SARS-CoV-2 vaccination in liver transplanted patients: The debate is open!. Journal 127 13.4 9 of Hepatology, 2021, Coffee Restores Expression of IncRNAs Involved in Steatosis and Fibrosis in a Mouse Model of 126 6.7 3 NAFLD. *Nutrients*, **2021**, 13, An international genome-wide meta-analysis of primary biliary cholangitis: Novel risk loci and 8 125 13.4 candidate drugs. Journal of Hepatology, 2021, 75, 572-581 Surveillance for hepatocellular carcinoma with a 3-months interval in "extremely high-risk" patients 2 124 3.3 does not further improve survival. Digestive and Liver Disease, 2021, Low influenza vaccination coverage in subjects with liver cirrhosis. An alert waiting for winter 123 19.7 season 2020-2021 during the COVID-19 pandemic. Journal of Medical Virology, 2021, 93, 2446-2452 Epidemiological trends and trajectories of MAFLD-associated hepatocellular carcinoma 2002-2033: 8 122 19.2 the ITA.LI.CA database.. Gut, 2021, Long-term albumin administration is not futile in patients with cirrhosis and uncomplicated ascites 121 13.4 not normalizing serum albumin concentration with treatment. Journal of Hepatology, 2020, 73, S738 Migratory flow and hepatitis delta infection in Italy: A new challenge at the beginning of the third 120 3.4 5 millennium. Journal of Viral Hepatitis, 2020, 27, 941-947 The Bisphenol A Induced Oxidative Stress in Non-Alcoholic Fatty Liver Disease Male Patients: A Clinical Strategy to Antagonize the Progression of the Disease. International Journal of 119 4.6 9 Environmental Research and Public Health, 2020, 17, Modeling the time-related fluctuations of AFP and PIVKA-II serum levels in patients with cirrhosis 6 118 3.8 undergoing surveillance for hepatocellular carcinoma. Cancer Biomarkers, 2020, 29, 189-196 A Hyper-Glycosylation of HBV Surface Antigen Correlates with HBsAg-Negativity at Immunosuppression-Driven HBV Reactivation in Vivo and Hinders HBsAg Recognition in Vitro. 6.2 117 4 Viruses, 2020, 12, Use of Telemedicine for Chronic Liver Disease at a Single Care Center During the COVID-19 116 7.6 9 Pandemic: Prospective Observational Study. Journal of Medical Internet Research, 2020, 22, e20874 The association between education level and chronic liver disease of any etiology. European Journal 115 3.9 5 of Internal Medicine, 2020, 75, 55-59

114	Incidence of HCC recurrence after DAA treatment for HCV in a multicentre Italian cohort study. Liver Cancer International, <b>2020</b> , 1, 12-24	0.8	1
113	The interpretation of liver function tests in pregnancy. <i>Bailliereks Best Practice and Research in Clinical Gastroenterology</i> , <b>2020</b> , 44-45, 101667	2.5	1
112	Plasma phospholipid dysregulation in patients with cystathionine-Isynthase deficiency. <i>Nutrition, Metabolism and Cardiovascular Diseases</i> , <b>2020</b> , 30, 2286-2295	4.5	2
111	Advanced liver disease outcomes after hepatitis C eradication by human immunodeficiency virus infection in PITER cohort. <i>Hepatology International</i> , <b>2020</b> , 14, 362-372	8.8	5
110	Incidence and risk factors of early HCC occurrence in HCV patients treated with direct acting antivirals: a prospective multicentre study. <i>Journal of Translational Medicine</i> , <b>2019</b> , 17, 292	8.5	26
109	HepaDisk - A new quality of life questionnaire for HCV patients. <i>Digestive and Liver Disease</i> , <b>2019</b> , 51, 1008-1015	3.3	2
108	Geographical pattern of chronic liver diseases in Italy: Results from two pooled national surveys. <i>European Journal of Internal Medicine</i> , <b>2019</b> , 61, 40-43	3.9	3
107	Real-life glecaprevir/pibrentasvir in a large cohort of patients with hepatitis C virus infection: The MISTRAL study. <i>Liver International</i> , <b>2019</b> , 39, 1852-1859	7.9	21
106	The concept of therapeutic hierarchy for patients with hepatocellular carcinoma: A multicenter cohort study. <i>Liver International</i> , <b>2019</b> , 39, 1478-1489	7.9	27
105	Liver stiffness assessment by transient elastography suggests high prevalence of liver involvement in common variable immunodeficiency. <i>Digestive and Liver Disease</i> , <b>2019</b> , 51, 1599-1603	3.3	2
104	Decreasing role of HCV and HBV infections as aetiological factors of hepatocellular carcinoma in Italy. <i>Infection</i> , <b>2019</b> , 47, 805-810	5.8	6
103	A snapshot of virological presentation and outcome of immunosuppression-driven HBV reactivation from real clinical practice: Evidence of a relevant risk of death and evolution from silent to chronic infection. <i>Journal of Viral Hepatitis</i> , <b>2019</b> , 26, 846-855	3.4	8
102	Role of Liver Stiffness Measurement in Predicting HCC Occurrence in Direct-Acting Antivirals Setting: A Real-Life Experience. <i>Digestive Diseases and Sciences</i> , <b>2019</b> , 64, 3013-3019	4	20
101	PS-083-Serum albumin concentration as guide for long-term albumin treatment in patients with cirrhosis and uncomplicated ascites: Lessons from the ANSWER study. <i>Journal of Hepatology</i> , <b>2019</b> , 70, e53	13.4	5
100	Evaluation of the Effect Derived from Silybin with Vitamin D and Vitamin E Administration on Clinical, Metabolic, Endothelial Dysfunction, Oxidative Stress Parameters, and Serological Worsening Markers in Nonalcoholic Fatty Liver Disease Patients. Oxidative Medicine and Cellular	6.7	23
99	Longevity, <b>2019</b> , 2019, 8742075  Ultrasound-based transient elastography improves the detection of liver disease in common variable immunodeficiency. <i>Journal of Allergy and Clinical Immunology: in Practice</i> , <b>2019</b> , 7, 2507-2508	5.4	1
98	Overview of Immune Checkpoint Inhibitors Therapy for Hepatocellular Carcinoma, and The ITA.LI.CA Cohort Derived Estimate of Amenability Rate to Immune Checkpoint Inhibitors in Clinical Practice. <i>Cancers</i> , <b>2019</b> , 11,	6.6	25
97	, and Extracts Modulate the Insulin Receptor Expression and Improve Hepatic Steatosis in NAFLD Patients: A Pilot Clinical Trial. <i>Nutrients</i> , <b>2019</b> , 11,	6.7	1

## (2018-2019)

96	Obeticholic acid for the treatment of non-alcoholic steatohepatitis: interim analysis from a multicentre, randomised, placebo-controlled phase 3 trial. <i>Lancet, The</i> , <b>2019</b> , 394, 2184-2196	40	425
95	The burden of HBV infection in HCV patients in Italy and the risk of reactivation under DAA therapy. <i>Digestive and Liver Disease</i> , <b>2019</b> , 51, 434-437	3.3	9
94	Utility of Tumor Burden Score to Stratify Prognosis of Patients with Hepatocellular Cancer: Results of 4759 Cases from ITA.LI.CA Study Group. <i>Journal of Gastrointestinal Surgery</i> , <b>2018</b> , 22, 859-871	3.3	17
93	Optimization of direct anti-viral agent treatment schedule: Focus on HCV genotype 3. <i>United European Gastroenterology Journal</i> , <b>2018</b> , 6, 225-237	5.3	3
92	Adherence to Barcelona Clinic Liver Cancer guidelines in field practice: Results of Progetto Epatocarcinoma Campania. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , <b>2018</b> , 33, 1123-1130	4	11
91	Frequent NS5A and multiclass resistance in almost all HCV genotypes at DAA failures: What are the chances for second-line regimens?. <i>Journal of Hepatology</i> , <b>2018</b> , 68, 597-600	13.4	23
90	Restaging Patients With Hepatocellular Carcinoma Before Additional Treatment Decisions: A Multicenter Cohort Study. <i>Hepatology</i> , <b>2018</b> , 68, 1232-1244	11.2	15
89	Dietary supplementation of vitamin D prevents the development of western diet-induced metabolic, hepatic and cardiovascular abnormalities in rats. <i>United European Gastroenterology Journal</i> , <b>2018</b> , 6, 1056-1064	5.3	17
88	Metabolic disorders across hepatocellular carcinoma in Italy. <i>Liver International</i> , <b>2018</b> , 38, 2028-2039	7.9	5
87	Recurrence of hepatocellular carcinoma after direct acting antiviral treatment for hepatitis C virus infection: Literature review and risk analysis. <i>Digestive and Liver Disease</i> , <b>2018</b> , 50, 1105-1114	3.3	26
86	Sustained virological response by direct antiviral agents in HCV leads to an early and significant improvement of liver fibrosis. <i>Antiviral Therapy</i> , <b>2018</b> , 23, 129-138	1.6	21
85	Laser ablation is superior to TACE in large-sized hepatocellular carcinoma: a pilot case-control study. <i>Oncotarget</i> , <b>2018</b> , 9, 17483-17490	3.3	5
84	Hepatitis C Virus Clearance in Older Adults. <i>Journal of the American Geriatrics Society</i> , <b>2018</b> , 66, 85-91	5.6	4
83	Patients with advanced hepatocellular carcinoma need a personalized management: A lesson from clinical practice. <i>Hepatology</i> , <b>2018</b> , 67, 1784-1796	11.2	65
82	PNPLA3 rs738409 Polymorphism Predicts Development and Severity of Hepatic Steatosis but Not Metabolic Syndrome in Celiac Disease. <i>Nutrients</i> , <b>2018</b> , 10,	6.7	11
81	Eradication of HCV in Renal Transplant Recipients and Its Effects on Quality of Life. <i>BioMed Research International</i> , <b>2018</b> , 2018, 8953581	3	6
80	Characteristics and Changes over Time of Alcohol-Related Chronic Liver Diseases in Italy. <i>Canadian Journal of Gastroenterology and Hepatology</i> , <b>2018</b> , 2018, 9151820	2.8	3
79	Direct-acting antivirals and hepatocellular carcinoma in chronic hepatitis C: A few lights and many shadows. <i>World Journal of Gastroenterology</i> , <b>2018</b> , 24, 2582-2595	5.6	35

78	Long-term albumin administration in decompensated cirrhosis (ANSWER): an open-label randomised trial. <i>Lancet, The</i> , <b>2018</b> , 391, 2417-2429	40	176
77	Multiclass HCV resistance to direct-acting antiviral failure in real-life patients advocates for tailored second-line therapies. <i>Liver International</i> , <b>2017</b> , 37, 514-528	7.9	71
76	A meta-analysis of single HCV-untreated arm of studies evaluating outcomes after curative treatments of HCV-related hepatocellular carcinoma. <i>Liver International</i> , <b>2017</b> , 37, 1157-1166	7.9	53
75	AISF position paper on nonalcoholic fatty liver disease (NAFLD): Updates and future directions. <i>Digestive and Liver Disease</i> , <b>2017</b> , 49, 471-483	3.3	179
74	Hepatic decompensation is the major driver of death in HCV-infected cirrhotic patients with successfully treated early hepatocellular carcinoma. <i>Journal of Hepatology</i> , <b>2017</b> , 67, 65-71	13.4	63
73	HCV clearance after direct-acting antivirals in patients with cirrhosis by stages of liver impairment: The ITAL-C network study. <i>Digestive and Liver Disease</i> , <b>2017</b> , 49, 1022-1028	3.3	13
72	Prevalence of and risk factors for HBV infection in a metropolitan Southern Italian area: Evidence for the effectiveness of universal Hepatitis B vaccination. <i>Digestive and Liver Disease</i> , <b>2017</b> , 49, 1257-12	6 <sup>3</sup> .3	6
71	Circulating SCCA-IgM complex is a useful biomarker to predict the outcome of therapy in hepatocellular carcinoma patients. <i>Scandinavian Journal of Clinical and Laboratory Investigation</i> , <b>2017</b> , 77, 448-453	2	8
70	Influence of universal HBV vaccination on chronic HBV infection in Italy: Results of a cross-sectional multicenter study. <i>Journal of Medical Virology</i> , <b>2017</b> , 89, 2138-2143	19.7	9
69	Viral Outcome in Patients with Occult HBV Infection or HCV-Ab Positivity Treated for Lymphoma. <i>Annals of Hepatology</i> , <b>2017</b> , 16, 198-206	3.1	12
68	Premature ovarian senescence and a high miscarriage rate impair fertility in women with HCV. <i>Journal of Hepatology</i> , <b>2017</b> ,	13.4	9
67	Ombitasvir, paritaprevir, and ritonavir, with or without dasabuvir, plus ribavirin for patients with hepatitis C virus genotype 1 or 4 infection with cirrhosis (ABACUS): a prospective observational study. <i>The Lancet Gastroenterology and Hepatology</i> , <b>2017</b> , 2, 427-434	18.8	13
66	Characteristics of liver cirrhosis in Italy: Evidence for a decreasing role of HCV aetiology. <i>European Journal of Internal Medicine</i> , <b>2017</b> , 38, 68-72	3.9	16
65	Impact of Diabetes on Outcomes of Sorafenib Therapy for Hepatocellular Carcinoma. <i>Targeted Oncology</i> , <b>2017</b> , 12, 61-67	5	15
64	Curative therapies are superior to standard of care (transarterial chemoembolization) for intermediate stage hepatocellular carcinoma. <i>Liver International</i> , <b>2017</b> , 37, 423-433	7.9	34
63	The evolutionary scenario of hepatocellular carcinoma in Italy: an update. <i>Liver International</i> , <b>2017</b> , 37, 259-270	7.9	50
62	Prevalence and risk factors of HCV infection in a metropolitan area in southern Italy: Tail of a cohort infected in past decades. <i>Journal of Medical Virology</i> , <b>2017</b> , 89, 291-297	19.7	31
61	Timing Strategies of Direct-Acting Antivirals and Biologics Administration in HCV-Infected Subjects with Inflammatory Bowel Diseases. <i>Frontiers in Pharmacology</i> , <b>2017</b> , 8, 867	5.6	7

60	Silibinin Restores NAD+ Levels and Induces the SIRT1/AMPK Pathway in Non-Alcoholic Fatty Liver. <i>Nutrients</i> , <b>2017</b> , 9,	6.7	53
59	Sex difference in the interaction of alcohol intake, hepatitis B virus, and hepatitis C virus on the risk of cirrhosis. <i>PLoS ONE</i> , <b>2017</b> , 12, e0185710	3.7	5
58	Incidence of DAA failure and the clinical impact of retreatment in real-life patients treated in the advanced stage of liver disease: Interim evaluations from the PITER network. <i>PLoS ONE</i> , <b>2017</b> , 12, e018	5 <del>3</del> 728	28
57	Gut microbiota and functional diseases of the gastrointestinal tract. <i>Minerva Gastroenterology</i> , <b>2017</b> , 63, 355-372	3	5
56	AISF position paper on liver transplantation and pregnancy: Women in Hepatology Group, Italian Association for the Study of the Liver (AISF). <i>Digestive and Liver Disease</i> , <b>2016</b> , 48, 860-8	3.3	14
55	Epidemiological and clinical scenario of chronic liver diseases in Italy: Data from a multicenter nationwide survey. <i>Digestive and Liver Disease</i> , <b>2016</b> , 48, 1066-71	3.3	25
54	AISF position paper on liver disease and pregnancy. <i>Digestive and Liver Disease</i> , <b>2016</b> , 48, 120-37	3.3	23
53	Hemostatic balance in patients with liver cirrhosis: Report of a consensus conference. <i>Digestive and Liver Disease</i> , <b>2016</b> , 48, 455-467	3.3	41
52	Development and Validation of a New Prognostic System for Patients with Hepatocellular Carcinoma. <i>PLoS Medicine</i> , <b>2016</b> , 13, e1002006	11.6	81
51	Effect of Red Wine Polyphenols on the Expression of Transthyretin in Murine Choroid Plexus. <i>Current Pharmaceutical Biotechnology</i> , <b>2016</b> , 17, 1008-15	2.6	1
50	Impact of Telaprevir in HCV Patients with Cirrhosis and RVR: Real-Life Data from Boceprevir or Telaprevir based "Triple Therapy" Experience in Southern Italy. <i>Reviews on Recent Clinical Trials</i> , <b>2016</b> , 11, 306-316	1.2	4
49	Osteoporosis across chronic liver disease. <i>Osteoporosis International</i> , <b>2016</b> , 27, 1967-77	5.3	20
48	Lack of evidence that adherence to standard of care therapy improves survival in subjects with hepatocellular carcinoma in clinical practice. <i>Journal of Medical Virology</i> , <b>2015</b> , 87, 1368-76	19.7	2
47	Current evidence in the field of the management with TNF-Inhibitors in psoriatic arthritis and concomitant hepatitis C virus infection. <i>Expert Opinion on Biological Therapy</i> , <b>2015</b> , 15, 641-50	5.4	26
46	Survival benefit of liver resection for patients with hepatocellular carcinoma across different Barcelona Clinic Liver Cancer stages: a multicentre study. <i>Journal of Hepatology</i> , <b>2015</b> , 62, 617-24	13.4	129
45	Coffee enhances the expression of chaperones and antioxidant proteins in rats with nonalcoholic fatty liver disease. <i>Translational Research</i> , <b>2014</b> , 163, 593-602	11	45
44	Determinants of alpha-fetoprotein levels in patients with hepatocellular carcinoma: implications for its clinical use. <i>Cancer</i> , <b>2014</b> , 120, 2150-7	6.4	45
43	An a priori prediction model of response to peginterferon plus ribavirin dual therapy in naMe patients with genotype 1 chronic hepatitis C. <i>Digestive and Liver Disease</i> , <b>2014</b> , 46, 818-25	3.3	8

42	Long-term safety of anti-TNF-In PsA patients with concomitant HCV infection: a retrospective observational multicenter study on 15 patients. <i>Clinical Rheumatology</i> , <b>2014</b> , 33, 273-6	3.9	53
41	Coffee and liver health. <i>Journal of Clinical Gastroenterology</i> , <b>2014</b> , 48 Suppl 1, S87-90	3	24
40	Asunaprevir, a protease inhibitor for the treatment of hepatitis C infection. <i>Therapeutics and Clinical Risk Management</i> , <b>2014</b> , 10, 493-504	2.9	22
39	Lack of evidence of viral reactivation in HBsAg-negative HBcAb-positive and HCV patients undergoing immunosuppressive therapy for psoriasis. <i>BMC Gastroenterology</i> , <b>2014</b> , 14, 214	3	20
38	Variation in genes encoding for interferon B and H in the prediction of HCV-1 treatment-induced viral clearance. <i>Liver International</i> , <b>2014</b> , 34, 1369-77	7.9	7
37	Estimation of lead-time bias and its impact on the outcome of surveillance for the early diagnosis of hepatocellular carcinoma. <i>Journal of Hepatology</i> , <b>2014</b> , 61, 333-41	13.4	84
36	Application of PTR-TOF-MS to investigate metabolites in exhaled breath of patients affected by coeliac disease under gluten free diet. <i>Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences</i> , <b>2014</b> , 966, 208-13	3.2	13
35	Identification of nalle HCV-1 patients with chronic hepatitis who may benefit from dual therapy with peg-interferon and ribavirin. <i>Journal of Hepatology</i> , <b>2014</b> , 60, 16-21	13.4	23
34	Hepatitis B and C virus reactivation in immunosuppressed patients with inflammatory bowel disease. <i>World Journal of Gastroenterology</i> , <b>2014</b> , 20, 3516-24	5.6	23
33	Hepatitis C virus infection in end stage renal disease and after kidney transplant. <i>Journal of Gastrointestinal and Liver Diseases</i> , <b>2014</b> , 23, 340-2	1.4	1
32	Vitamin D levels and chronic hepatitis C. <i>E-SPEN Journal</i> , <b>2013</b> , 8, e169-e174		2
31	Garlic extract attenuating rat liver fibrosis by inhibiting TGF-11. Clinical Nutrition, 2013, 32, 252-8	5.9	24
30	Effect of immunosuppressive therapy on patients with inflammatory bowel diseases and hepatitis B or C virus infection. <i>Journal of Viral Hepatitis</i> , <b>2013</b> , 20, 200-8	3.4	23
29	Rise and fall of HCV-related hepatocellular carcinoma in Italy: a long-term survey from the ITA.LI.CA centres. <i>Liver International</i> , <b>2013</b> , 33, 1420-7	7.9	12
28	Rapid "breath-print" of liver cirrhosis by proton transfer reaction time-of-flight mass spectrometry. A pilot study. <i>PLoS ONE</i> , <b>2013</b> , 8, e59658	3.7	53
27	Sustained virological response: a milestone in the treatment of chronic hepatitis C. <i>World Journal of Gastroenterology</i> , <b>2013</b> , 19, 2793-8	5.6	55
26	Concomitant interferon-alpha and chemotherapy in hepatitis C and colorectal cancer: a case report. <i>In Vivo</i> , <b>2013</b> , 27, 527-9	2.3	12
25	Analysis of breath by proton transfer reaction time of flight mass spectrometry in rats with steatohepatitis induced by high-fat diet. <i>Journal of Mass Spectrometry</i> , <b>2012</b> , 47, 1098-103	2.2	21

## (2001-2011)

24	Hepatitis B virus infection and immunosuppressive therapy in patients with inflammatory bowel disease. <i>Digestive and Liver Disease</i> , <b>2011</b> , 43 Suppl 1, S40-8	3.3	28
23	Etiology of and risk factors for transient and persistent aminotransferase elevation in a population of virus-free blood donors: a multicentre study. <i>Digestive and Liver Disease</i> , <b>2010</b> , 42, 441-5	3.3	2
22	Garlic extract prevents CCl(4)-induced liver fibrosis in rats: The role of tissue transglutaminase. <i>Digestive and Liver Disease</i> , <b>2010</b> , 42, 571-7	3.3	33
21	Retrospective, observational, multicentre study on an Italian population affected by chronic hepatitis C who failed to clear HCV-RNA after the combined therapy (PEG-IFN and ribavirin): NADIR study. <i>Journal of Viral Hepatitis</i> , <b>2010</b> , 17, 427-34	3.4	4
20	Coffee reduces liver damage in a rat model of steatohepatitis: the underlying mechanisms and the role of polyphenols and melanoidins. <i>Hepatology</i> , <b>2010</b> , 52, 1652-61	11.2	157
19	Dietary trans-resveratrol bioavailability and effect on CCl4-induced liver lipid peroxidation. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , <b>2009</b> , 24, 618-22	4	27
18	Foods and liver health. <i>Molecular Aspects of Medicine</i> , <b>2008</b> , 29, 144-50	16.7	38
17	Efficacy of loco-regional ablation therapy of HCC in a population of liver transplanted patients. <i>Digestive Diseases and Sciences</i> , <b>2008</b> , 53, 1131-7	4	9
16	Liver transplantation and recurrent hepatocellular carcinoma: predictive value of nodule size in a retrospective and explant study. <i>Transplantation</i> , <b>2006</b> , 81, 1532-41	1.8	61
15	Dietary antioxidant compounds and liver health. <i>Critical Reviews in Food Science and Nutrition</i> , <b>2004</b> , 44, 575-86	11.5	208
14	Oxidative status in chronic hepatitis C: the influence of antiviral therapy and prognostic value of serum hydroperoxide assay. <i>Free Radical Research</i> , <b>2004</b> , 38, 573-80	4	19
13	Tamaka harad Guarkianal Gand on interferon adjuvent in UCV and in time thereon, Javanal of Clinical		
	Tomato-based functional food as interferon adjuvant in HCV eradication therapy. <i>Journal of Clinical Gastroenterology</i> , <b>2004</b> , 38, S118-20	3	12
12		3-4	12
12	Gastroenterology, 2004, 38, S118-20  Increased serum reverse triiodothyronine levels at diagnosis of hepatocellular carcinoma in		
	Increased serum reverse triiodothyronine levels at diagnosis of hepatocellular carcinoma in patients with compensated HCV-related liver cirrhosis. <i>Clinical Endocrinology</i> , <b>2003</b> , 58, 207-12  The addition of ribavirin to interferon-alpha therapy in patients with hepatitis C virus-related chronic hepatitis does not modify the thyroid autoantibody pattern but increases the risk of	3.4	19
11	Increased serum reverse triiodothyronine levels at diagnosis of hepatocellular carcinoma in patients with compensated HCV-related liver cirrhosis. <i>Clinical Endocrinology</i> , <b>2003</b> , 58, 207-12  The addition of ribavirin to interferon-alpha therapy in patients with hepatitis C virus-related chronic hepatitis does not modify the thyroid autoantibody pattern but increases the risk of developing hypothyroidism. <i>European Journal of Endocrinology</i> , <b>2002</b> , 146, 743-9  Use of N,N-dimethyl-p-phenylenediamine to evaluate the oxidative status of human plasma. <i>Free</i>	3.4	19 58
11	Increased serum reverse triiodothyronine levels at diagnosis of hepatocellular carcinoma in patients with compensated HCV-related liver cirrhosis. <i>Clinical Endocrinology</i> , <b>2003</b> , 58, 207-12  The addition of ribavirin to interferon-alpha therapy in patients with hepatitis C virus-related chronic hepatitis does not modify the thyroid autoantibody pattern but increases the risk of developing hypothyroidism. <i>European Journal of Endocrinology</i> , <b>2002</b> , 146, 743-9  Use of N,N-dimethyl-p-phenylenediamine to evaluate the oxidative status of human plasma. <i>Free Radical Research</i> , <b>2002</b> , 36, 869-73  Incidence of side effects during therapy with different types of alpha interferon: a randomised controlled trial comparing recombinant alpha 2b versus leukocyte interferon in the therapy of	3·4 6.5	19 58 56

6	Alpha-glutathione transferases in HCV-related chronic hepatitis: a new predictive index of response to interferon therapy?. <i>Journal of Hepatology</i> , <b>1998</b> , 28, 390-5	13.4	42
5	Determination of plasma alpha-glutathione S-transferases in patients with HCV-related chronic infection: its significance and possible clinical relevance. <i>Liver</i> , <b>1998</b> , 18, 166-72		11
4	Chronic hepatitis C long-term responders to human leukocyte interferon-alpha therapy: persistence of a sustained biochemical and virological response during 5 years of surveillance. <i>European Journal of Gastroenterology and Hepatology</i> , <b>1998</b> , 10, 399-403	2.2	6
3	It is futile to use interferon in HCV-related chronic hepatitis with viremia levels above $3 \times 10(6)$ eq/ml. <i>Infection</i> , <b>1997</b> , 25, 190-1	5.8	
2	Basal core-IgM antibodies to hepatitis C virus are not predictive of successful alpha-interferon therapy. <i>Journal of Hepatology</i> , <b>1995</b> , 22, 377	13.4	2
1	Prevalence of hepatitis C virus infection in the household contacts of patients with HCV-related chronic liver disease. <i>Infection</i> , <b>1994</b> , 22, 183-6	5.8	21